|
Original version Date:24/8/2016
|
| bet | 412/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Original version Date:24/8/2016
|
Author: NMF Consensus Group
|
Current Version number: 2
|
Current Version Date: 19/7/2018
|
Risk Rating: Low
|
Due for Review: 19/7/2023
|
Approval by: DTC
|
Approval Date: TBA
|
Palivizumab |
Revision Date : 16/11/2020
|
Approved: TC,KOH
|
Alert
|
Cost effectiveness is unclear. Use of this drug should be done in conjunction with local hospital guidelines. Consider the infant’s susceptibility to severe RSV disease, RSV prevalence and seasonality, risk of exposure including siblings and social factors, and parental preference.
|
Indication
|
Prophylaxis against RSV infection in at risk infants
|
Action
|
Humanised monoclonal antibody that neutralises and inhibits fusion of respiratory syncytial virus (RSV) with the host cell, preventing its replication.
|
Drug type
|
Humanised monoclonal antibody
|
Trade name
|
Synagis solution for injection. [1]
|
Presentation
|
100 mg/mL; 0.5 mL (50 mg), 1 mL (100 mg) vial
|
Dose
|
15 mg/kg once per month during periods of RSV risk (e.g. May to August in Southern Australia). Preferably administer first dose before RSV season (e.g. April in southern Australia).
|
Dose adjustment
|
Therapeutic hypothermia: not applicable.
ECMO: after cardiopulmonary bypass surgery, give a dose once child is stable (serum concentration markedly reduced after these procedures).
Renal: not applicable.
Hepatic: not applicable.
|
Maximum dose
|
Monthly doses of 15 mg/kg to maximum 5 doses. Infants discharged during RSV season may receive fewer doses.
|
|
|
| |
